Adial Reports Q2 2026 Results, Acquires Azora Therapeutics
Adial Pharmaceuticals reported Q2 2026 financial results and announced the acquisition of Azora Therapeutics and a $32 million private placement to advance its Ahr agonist candidate for ulcerative colitis.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day